Antibody Humanization
Antibody humanization involves modifying mouse-derived antibodies through gene cloning and DNA recombination, replacing the majority of their amino acid sequences with human counterparts. This process retains the affinity and specificity of the original mouse monoclonal antibody while significantly reducing its immunogenicity. As a result, humanized antibodies are less likely to trigger immune responses in humans and are essential for the development of therapeutic antibodies. LIFESCT offers reliable antibody humanization services based on CDR grafting or surface resurfacing strategies. With an efficient workflow in place, we can complete humanization in as little as three weeks, while ensuring that the humanized antibodies retain the full affinity and specificity of their parental counterparts.
Key Features
• Antibody engineering guided by bioinformatics and structural biology through computer-aided design
• Simultaneous optimization of both heavy and light chains, achieving >90% humanization
• Maintains affinity comparable to the original antibody
• Humanized antibody delivery in as fast as 3 weeks
Specifications
| Item | Description | EDT |
| 1. Sequence Analysis | • Construct 3D antibody structure models • Germline Selection • CDR grafting with key residue back mutations • Removal of PTM sites (optional) |
1 week |
| 2. Antibody Expression | • Gene synthesis & vector construction • High-throughput expression in mammalian system or small-scale antibody expression |
2 weeks |
| 3. Affinity Measurement | • ELISA/BLI-based affinity screening from culture supernatant • Biacore validation |
1 week |
| 4. Antibody Purification | • Small-scale antibody expression and purification • QC |
1 week |
Quote Guide
To inquire about this service, please choose one of the options below:
1. Fill out Enquiry Form to submit your request.
2. Download the Quote Form and send to sales@lifesct.com.
3. Register and log in to your account to submit your request via Service Quote system.
Deliverables
1. 2–3 humanized antibody variants(at least one with affinity comparable to the original antibody)
2. Cloned plasmids
3. Humanization design report
4. 2–3 antibody samples (1 mg each)
5. COA report